St. Josef-Hospital

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type ...

Glucagon-like peptide 1 (GLP-1)

The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimu...

Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors

Over the last few years, incretin‐based therapies have emerged as important agents in the treatment of type 2 diabetes ( T2D ). These agents exert their effect via the incretin ...

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis